Literature DB >> 23562620

Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes.

Camille M Konopnicki1, Leslie J Dickmann, Jeffrey M Tracy, Robert H Tukey, Larry C Wienkers, Robert S Foti.   

Abstract

Previous experiments performed in recombinant systems have suggested that protein-protein interactions occur between the UGTs and may play a significant role in modulating enzyme activity. However, evidence of UGT protein-protein interactions either in vivo or in more physiologically relevant in vitro systems has yet to be demonstrated. In this study, we examined oligomerization and its ability to affect glucuronidation in plated human hepatocytes. siRNA down regulation experiments and activity studies were used to examine changes in metabolite formation of one UGT isoform due to down regulation of a second UGT isoform. Selective siRNA directed towards UGT1A9 or UGT2B7 resulted in significant and selective decreases in their respective mRNA levels. As expected, the metabolism of the UGT1A9 substrate propofol decreased with UGT1A9 down regulation. Interestingly, UGT1A9 activity, but not UGT1A9 mRNA expression, was also diminished when UGT2B7 expression was selectively inhibited, implying potential interactions between the two isoforms. Minor changes to UGT1A4, UGT2B4 and UGT2B7 activity were also observed when UGT1A9 expression was selectively down regulated. To our knowledge, this represents the first piece of evidence that UGT protein-protein interactions occur in human hepatocytes and suggests that expression levels of UGT2B7 may directly impact the glucuronidation activity of selective UGT1A9 substrates.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562620      PMCID: PMC4059507          DOI: 10.1016/j.abb.2013.03.012

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  36 in total

1.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.

Authors:  M G Soars; B Burchell; R J Riley
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

Review 2.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

3.  Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling.

Authors:  Benjamin C Lewis; Peter I Mackenzie; John O Miners
Journal:  Biochem Pharmacol       Date:  2011-09-14       Impact factor: 5.858

4.  Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment.

Authors:  Juntyma J Engtrakul; Robert S Foti; Timothy J Strelevitz; Michael B Fisher
Journal:  Drug Metab Dispos       Date:  2005-07-27       Impact factor: 3.922

5.  Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme.

Authors:  Mika Kurkela; J Arturo García-Horsman; Leena Luukkanen; Saila Mörsky; Jyrki Taskinen; Marc Baumann; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

6.  Interaction between cytochrome P450 and other drug-metabolizing enzymes: evidence for an association of CYP1A1 with microsomal epoxide hydrolase and UDP-glucuronosyltransferase.

Authors:  K I Taura; H Yamada; Y Hagino; Y Ishii; M A Mori; K Oguri
Journal:  Biochem Biophys Res Commun       Date:  2000-07-14       Impact factor: 3.575

7.  Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

Authors:  Brooke M VandenBrink; Robert S Foti; Dan A Rock; Larry C Wienkers; Jan L Wahlstrom
Journal:  Drug Metab Dispos       Date:  2011-06-22       Impact factor: 3.922

8.  Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic pathways for 7-ethoxycoumarin in human liver microsomes treated with alamethicin.

Authors:  Michael B Fisher; David Jackson; Andreas Kaerner; Steven A Wrighton; Anthony G Borel
Journal:  Drug Metab Dispos       Date:  2002-03       Impact factor: 3.922

9.  Glucuronidation of propofol and its analogs by human and rat liver microsomes.

Authors:  Makiko Shimizu; Yoshiaki Matsumoto; Masahiro Tatsuno; Masamichi Fukuoka
Journal:  Biol Pharm Bull       Date:  2003-02       Impact factor: 2.233

10.  Effects of propofol analogs on glucuronidation of propofol, an anesthetic drug, by human liver microsomes.

Authors:  Makiko Shimizu; Yoshiaki Matsumoto; Hiroshi Yamazaki
Journal:  Drug Metab Lett       Date:  2007-01
View more
  1 in total

1.  Reduction of p53 by knockdown of the UGT1 locus in colon epithelial cells causes an increase in tumorigenesis.

Authors:  Miao Liu; Shujuan Chen; Mei-Fei Yueh; Guangji Wang; Haiping Hao; Robert H Tukey
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.